BlackRock Institutional Trust’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock Institutional Trust’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$490K	Buy	18,661 +3,238	+21%	+$101K	﹤0.01%	3464
2016 Q3	$625K	Hold	15,423	–	–	﹤0.01%	3432
2016 Q2	$819K	Buy	15,423 +1,571	+11%	+$87.7K	﹤0.01%	3379
2016 Q1	$827K	Hold	13,852	–	–	﹤0.01%	3332
2015 Q4	$1.34M	Buy	13,852 +3,631	+36%	+$241K	﹤0.01%	3249
2015 Q3	$543K	Buy	+10,221	New	+$683K	﹤0.01%	3481
2015 Q2	–	Sell	-6,650	Closed	-$493K	–	3910
2015 Q1	$493K	Buy	6,650 +587	+10%	+$69.8K	﹤0.01%	3506
2014 Q4	$1.07M	Sell	6,063 -373	-6%	-$70.8K	﹤0.01%	3336
2014 Q3	$1.29M	Buy	6,436 +778	+14%	+$154K	﹤0.01%	3237
2014 Q2	$1.23M	Buy	+5,658	New	+$1.88M	﹤0.01%	3378

Other funds holding ATNM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Institutional Trust's ATNM Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Actinium Pharmaceuticals (ATNM) stake by 21% in Q4 2016, buying an estimated $101K and bringing the position to 18,661 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

BlackRock Institutional Trust first reported a position in ATNM in Q2 2014 and has held it in 10 quarters since. The position peaked at $1.34M in Q4 2015. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

BlackRock Institutional Trust held 18,661 shares of Actinium Pharmaceuticals worth $490K as of Q4 2016.
BlackRock Institutional Trust bought 3,238 Actinium Pharmaceuticals shares in Q4 2016, an estimated $101K.
Actinium Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3464 holding.
BlackRock Institutional Trust first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 10 quarters since.
BlackRock Institutional Trust's Actinium Pharmaceuticals position peaked at $1.34M in Q4 2015.
30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.